

Patitioner's Docket No. MPI94-008CP2DV2CN5M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Adams, Julian, et al  
Application No.: 10/730231 Group No.:  
Filed: December 8, 2003 Examiner:  
For: BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL**

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (2 pages);
  - b. Response to Notice of Informal Application (2 pages);
  - c. Copy of Notice of Informal Application (1 page);
  - d. Statement Under 37 CFR 3.73(b) (1 page); and
  - e. Return Postcard.

**STATUS**

2. Applicant is other than a small entity.

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: June 2, 2004

Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI94-008CP2DV2CN5M


**FEE DEFICIENCY**

3. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

June 2, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Janice M. Klunder  
Janice M. Klunder, Ph.D.  
Registration No. 41,121  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-551-3699  
Facsimile - 617-551-8820



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/96 (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Julian Adams et al.

Application No./Patent No.: 10/730,231 Filed/Issue Date: December 8, 2003

Entitled: Boronic Ester and Acid Compounds, Synthesis and Uses

Millennium Pharmaceuticals, Inc. \_\_\_\_\_, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or

2. ☐ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is \_\_\_\_\_ %  
in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

**OR**

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Julian Adams, et al. To: ProScript, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel 7882, Frame 0067, or for which a copy thereof is attached.

2. From: ProScript, Inc. To: Leukosite, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel 011433, Frame 0639, or for which a copy thereof is attached.

3. From: Leukosite, Inc. To: Millennium Pharmaceuticals, Inc.

The document was recorded in the United States Patent and Trademark Office at  
Reel 011502, Frame 0845, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 2, 2004

Date

(617) 551-8604

Telephone number

Scott A. Brown

Typed or printed name

Signature

Vice President, Chief Patent Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.